Atrial fibrillation (AF) and chronic heart failure (CHF) are two major and even growing cardiovascular conditions that often coexist. However, few data are available to guide treatment of AF in ...

atrial fibrillation. Circulation. 2002;106(1):14-16. 2. January CT, Wann LS, Alpert JS, et al; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial ...

Researchers sought to determine the relationship among hospitalization for COPD exacerbation, AF burden, and risk for subsequent stroke.

Abbott has reported new data from its prospective, non-randomised Volt CE Mark Study, indicating that individuals treated ...

The management of atrial fibrillation (AF) focuses on control of heart rate, correction of rhythm disturbance, prophylaxis of thromboembolism, treatment of underlying disorders, and ...

Atrial fibrillation is the most common chronic arrhythmia. It is characterized by erratic atrial electrical activity with atrial rates of 400 to 600 beats per minute. The P wave is absent on the ...

Pulmonary embolism (PE) is a significant cause of morbidity and mortality, particularly in patients classified as acute, ...

SGLT2 inhibitors, compared with GLP1 agonists, significantly lower risk for atrial fibrillation in patients with type 2 diabetes.

Abbott (NYSE: ABT) has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months ...

There is an important need for a more effective and safer antiarrhythmic drug for the acute management of AF." Meeting the Unmet Need for Innovative AF Therapies Atrial fibrillation is a serious ...

One-year clinical trial data for the next-generation, investigational, Sphere-360™ single-shot PFA catheter show impressive safety, performance, and efficiency results for paroxysmal AfibDual-energy ...

The trial – sponsored by the University of Liverpool – will collect data from acute ... atrial fibrillation research, and would help inform clinical practice and improve our care and ...